Back to discover
Drug

Activated charcoal

In clinical development
Emerging researchLate-stage development
Also known as Actidose, Activated Charcoal with Sorbitol, Activated carbon, Active Carbon+24 more

Actidose, Activated Charcoal with Sorbitol, Activated carbon, Active Carbon, Adsorbent charcoal, CHARCOAL,ACTIVATED, Carbo activates, Carbo activatus, Carbon, Activated, Carbon, decolorizing, Carbón activado, CharcoCaps, Charcoaid, Charcoaid 2000, Charcoaid-G, Charcoal Plus DS, Charcoal activated, Charcoal, Activated, Charcoal-activated, Decolorizing carbon, Decolourising carbon, Flatulex, Insta-Char, Liqui-Char, Liqui-Char with Sorbitol, Medicinal carbon, Medicinal charcoal, carbono.

RxNorm272UNII2P3VWU3H10
1
Research papers
4
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Efficient removal of regorafenib from aqueous solutions using KOH-activated hazelnut husk-derived activated carbon: adsorption mechanism, kinetics, isotherms and thermodynamics

Industry2026-08-04Nature — Environmental Sciences

Sustainable sludge derived activated carbon polyaniline composite removes lead and cadmium from industrial wastewater

Industry2026-08-04Nature — Environmental Sciences

Valorization of agricultural hazelnut waste into high-surface-area activated carbon: sustainable methodology for accurate VOC capture and thermodynamic assessment

Industry2026-07-28Nature — Environmental Sciences

Development and application of a poly (sodium p-styrenesulfonate-co-acrylic acid) / Ficus leaves–derived activated carbon composite for the efficient removal of 4-nitrophenol from aqueous solutions

Industry2026-07-24Nature — Environmental Sciences

A high temperature slow pyrolytic synthesis of Matteuccia struthiopteris derived activated carbon for high-performance supercapacitors

Industry2026-07-10Nature — Environmental Sciences

Adsorption of cationic and anionic dyes using chemically modified activated carbon from agricultural waste

Industry2026-07-04Nature — Environmental Sciences

CHARPP (Activated CHARcoal in Poisoned Patient): RCT Pilot Study

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

Clinical trial2026-05-14Results expected Q2 2027 · ClinicalTrials.gov

Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients

Clinical trial2025-11-01Primary completion · ClinicalTrials.gov

The Effect of Probiotics Versus Activated Charcoal in the Management of Chronic Kidney Disease Patients Suffering From Uremic Pruritus.

Clinical trial2025-02-01Primary completion · ClinicalTrials.gov

Safety of Oral Activated Charcoal and Its Effect on the Gut Microbiome In Patients With Lung Cancer Undergoing Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)

Clinical trial2025-01-01Withdrawn · ClinicalTrials.gov

Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels.

Research2012-08-17Clinical toxicology (Philadelphia, Pa.)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Activated charcoal
Aliases & brands
ActidoseActivated Charcoal with SorbitolActivated carbonActive CarbonAdsorbent charcoalCHARCOAL,ACTIVATEDCarbo activatesCarbo activatusCarbon, ActivatedCarbon, decolorizingCarbón activadoCharcoCapsCharcoaidCharcoaid 2000Charcoaid-GCharcoal Plus DSCharcoal activatedCharcoal, ActivatedCharcoal-activatedDecolorizing carbonDecolourising carbonFlatulexInsta-CharLiqui-CharLiqui-Char with SorbitolMedicinal carbonMedicinal charcoalcarbono
RxNorm CUI
272
UNII
2P3VWU3H10

Clinical trials

17 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
17
registered trials across all phases
LATEST COMPLETION 2024
4
Active studies
3
Recruiting
6
Late-stage (III+)
9
Completed
4
Discontinued
PHASE DISTRIBUTIONn = 17
Phase 17Phase 24Phase 2 / 31Phase 31Phase 43Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

CHARPP (Activated CHARcoal in Poisoned Patient): RCT Pilot Study

RecruitingPH IVLaval Universityn=1002027

Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants

WithdrawnPH IVUniversity Hospital, Angers2024

Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy: A Randomized Crossover Trial

CompletedPH IVState University of New York - Upstate Medical Universityn=52023

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

Active, not recruitingPH IIIKey trialSanofin=1,6552027

Evaluation of Protective Effect of Activated Charcoal and Probiotic Against Progression of Chronic Kidney Disease

Unknown statusPH II/IIIWaleed Khaild Rahman Kareem Al-kabin=602023

Recent completions

Trials that read out recently, adding to the completed evidence base.

Comparative Bioavailability Study of Budesonide After Inhalation of Budesonide 1 Mg / 2 Ml Nebuliser Suspension (Test Product 08P1707F0): Administration Without and with Activated Charcoal and Inhalation of Pulmicort® 1.0 Mg / 2 Ml Suspension (Reference Product) in Healthy Subjects

CompletedPH IUnither Pharmaceuticals, Francen=242024

Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy: A Randomized Crossover Trial

CompletedPH IVState University of New York - Upstate Medical Universityn=52023

Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.

CompletedPH ICentre Hospitalier Universitaire de Saint Etiennen=122022

A Single-center, Double-blind for Cenerimod, Open-label for Moxifloxacin, Placebo-controlled, Parallel-group, Randomized Study in Healthy Male and Female Subjects to Investigate I: the Effect of Cenerimod on the QTc Interval II: the Effect of Cenerimod on the Pharmacokinetics of Combined Oral Contraceptives III: the Effect of Charcoal on the Pharmacokinetics of Cenerimod.

CompletedPH IViatris Innovation GmbHn=972021

A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects

CompletedPH IGlaxoSmithKlinen=222016

A Single-Center, Open-Label, Two-Period Crossover Study to Investigate the Effect of Multiple Doses of Activated Charcoal on the Pharmacokinetics of a Single Oral Dose of RO4995819 in Healthy Subjects.

CompletedPH IHoffmann-La Rochen=262012

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • Clinical toxicology (Philadelphia, Pa.)1
Leading researchers
  • Chang AS1
  • Matthews AS1
  • Morgan BW1
  • Reedy SJ1
  • Skinner CG1
Leading institutions
free-text, unnormalised
  • Madigan Army Medical Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials